(Q39862726)

15 September 2017

title

Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge (English)

1 reference

15 September 2017

0 references

Manpreet Kaur

1

1 reference

15 September 2017

Anant Rai

series ordinal

2

1 reference

15 September 2017

Rakesh Bhatnagar

series ordinal

3

1 reference

15 September 2017

language of work or name

English

0 references

publication date

6 February 2009

1 reference

15 September 2017

1 reference

15 September 2017

volume

27

1 reference

15 September 2017

issue

15

1 reference

15 September 2017

page(s)

2128-2137

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

15 September 2017

1 reference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Rabies DNA vaccination of non-human primates: post-exposure studies using gene gun methodology that accelerates induction of neutralizing antibody and enhances neutralizing antibody titers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Immunization of dogs and cats with a DNA vaccine against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Immunization of dogs with a DNA vaccine induces protection against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Post-exposure DNA vaccination protects mice against rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Field trials of a very potent rabies DNA vaccine which induced long lasting virus neutralizing antibodies and protection in dogs in experimental conditions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Rabies DNA vaccine in the horse: strategies to improve serological responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Post-exposure therapy in mice against experimental rabies: a single injection of DNA vaccine is as effective as five injections of cell culture-derived vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Enhancing DNA immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

DNA vaccination against tuberculosis: expression of a ubiquitin-conjugated tuberculosis protein enhances antimycobacterial immunity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Cortisone-evoked decrease of acid-β-galactosidase, β-glucuronidase, N-acetyl-β-glucosaminidase and arylsulphatase in the ileum of suckling rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Breaking down the wall: fractionation of mycobacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

DNA vaccine for rabies: relevance of the trans-membrane domain of the glycoprotein in generating an antibody response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Evaluation of the anti-tuberculosis activity generated by different multigene DNA vaccine constructs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Regulating protein degradation by ubiquitination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Comparison of rabies virus G proteins produced by cDNA-transfected animal cells that display either inducible or constitutive expression of the gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Immune responses to nucleic acid vaccines to rabies virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Use of mouse anti-rabies monoclonal antibodies in postexposure treatment of rabies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

MHC class I-restricted CTL responses to exogenous antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

DNA vaccines: immunology, application, and optimization*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Alternative processing of endogenous or exogenous antigens extends the immunogenic, H-2 class I-restricted peptide repertoire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Capture and processing of exogenous antigens for presentation on MHC molecules.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Characterization of MHC class II-presented peptides generated from an antigen targeted to different endocytic compartments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Multiple antigen-specific processing pathways for activating naive CD8+ T cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Characterization of HPV-16 E6 DNA vaccines employing intracellular targeting and intercellular spreading strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Targeting antigen to MHC Class I and Class II antigen presentation pathways for malaria DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

Genetic immunization: a new era in vaccines and immune therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.01.128

7 January 2021

inferred from DOI database lookup

Rabies virus glycoprotein. II. Biological and serological characterization

1 reference

12 December 2020

In vivo priming by DNA injection occurs predominantly by antigen transfer.

1 reference

12 December 2020

Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine

1 reference

12 December 2020

Development of rabies DNA vaccine using a recombinant plasmid

1 reference

12 December 2020

DNA vaccines encoding full-length or truncated Neu induce protective immunity against Neu-expressing mammary tumors

1 reference

12 December 2020

Rabies: a new look at an old disease

1 reference

12 December 2020

Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences

1 reference

12 December 2020

Tissue distribution of a plasmid DNA encoding Hsp65 gene is dependent on the dose administered through intramuscular delivery

1 reference

12 December 2020

10.1016/J.VACCINE.2009.01.128

Identifiers

DOI

1 reference

15 September 2017

1 reference